A version of Third Wave Technologies’ flagship Invader DNA and RNA detection system would be available with microfluidic technology made by 3M under a supply pact with 3M Bioanalytical Technologies, the companies said last week.

Third Wave spokesman Rod Hise said the two companies would produce a microfluidic card equipped with an Invader assay. He would not discuss product applications and timelines until “sometime in the fourth quarter.” The product, if successful, may eventually share a market with ABI’s TaqMan.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.